Taskinen MR, et al. - Researchers tested alirocumab (a monoclonal antibody to proprotein convertase subtilisin/kexin type 9) in terms of efficacy and safety in patients with type 2 diabetes mellitus (T2DM) with vs without mixed dyslipidaemia (MDL, defined as baseline low-density lipoprotein cholesterol [LDL-C] ≥ 70 mg/dL [1.8 mmol/L] and triglycerides ≥150 mg/dL [1.7 mmol/L]). According to MDL status, they pooled data from 812 individuals with T2DM, from the placebo-controlled, 78-week, phase 3 ODYSSEY LONG TERM trial of alirocumab 150 mg every 2 weeks on a background of maximally tolerated statins ± other lipid-lowering therapies. They found that the safety, tolerability, and efficacy of alirocumab for reducing LDL-C and other lipids was similar between individuals with T2DM and with vs without MDL.